Skip to main content
Clinical Trials/ACTRN12622000522718
ACTRN12622000522718
Not yet recruiting
Phase 1

Comparison of the efficacy of two triple therapy topical combinations in the treatment of melasma in adults

Michelle Rodrigues0 sites20 target enrollmentApril 1, 2022

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Michelle Rodrigues
Enrollment
20
Status
Not yet recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 1, 2022
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Michelle Rodrigues

Eligibility Criteria

Inclusion Criteria

  • Patient clinically diagnosed with melasma
  • \- If patient is of childbearing age, she will be required to use a reliable contraceptive for at least 1 month and agree not to change her contraceptive status for the duration of the study
  • \- Patient who has signed the written informed consent form for study participation

Exclusion Criteria

  • \- Women who are pregnant or breast\-feeding or who are planning for pregnancy during the course of the study. (A urine b\-HCG or urine dipstick test will be performed)
  • \- Patient with another pigmentation disorder on the face.
  • \- Patient with other dermatoses that may interfere with the evaluation or application of the products involved in the study.
  • \- Patient who has used a depigmentation agent in the month prior to inclusion.
  • \- Patient who has used a local corticosteroid on the skin, eyes, nose or mouth (inhaled corticosteroid) or systemic corticosteroids during the month prior to inclusion.
  • \- Patient who has used local tretinoin or hydroquinone in the month prior to inclusion.
  • \- Patient on chronic anti\-inflammatory therapies (patient accepted into study if cumulative NSAID use is less than 10 days over the duration of the study).
  • \- Patient with a clinically significant history of allergy, especially to the components of the products studied.
  • \- Vulnerable persons including people under the age of 18 and those who are unable to take care of or protect themselves against harm or exploitation.
  • \- Patient being in a situation that, in the investigator's opinion, may interfere with optimal participation in the study.

Outcomes

Primary Outcomes

Not specified

Similar Trials